Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Workday
WDAY
5
Lantheus
LNTH
US OptionsDetailed Quotes
RARE250516P22500
- 0.00
- 0.000.00%
15min DelayClose Apr 30 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover0.00%IV42.28%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma18.13Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Ultragenyx Pharmaceutical Newsroom
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Barclays
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $80
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $80
BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating
Wedbush Maintains Ultragenyx Pharmaceutical(RARE.US) With Hold Rating, Cuts Target Price to $39
Truist Financial Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $117
Ultragenyx Pharma Is Maintained at Overweight by JP Morgan
Ultragenyx Pharmaceutical Analyst Ratings
Piper Sandler Initiates Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $115
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Piper Sandler
Morgan Stanley Initiates Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $64
Ultragenyx Pharma Price Target Maintained With a $118.00/Share by Cantor Fitzgerald
Ultragenyx Pharmaceutical Analyst Ratings
Cantor Fitzgerald Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $118
Analysts Offer Insights on Healthcare Companies: Icon (ICLR), Pediatrix Medical Group (MD) and Ultragenyx Pharmaceutical (RARE)
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $95
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $136
Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call